KORU Medical Systems, Inc.
NASDAQ:KRMDMedical - Instruments & Supplies
+$0.06 today
- Market cap
- $149.64M
- Beta
- 0.42
- P/E (TTM)
- -80.2
- EPS (TTM)
- -$0.05
Volume 0.19M
Average 0.13M
KRMD Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
KORU Medical Systems, Inc.NASDAQ: KRMD
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $681.51K fell 2.3% year over year, ahead of the -24.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 29.9% from the prior quarter. Over 3 fiscal years it compounded at -4.1% a year.
Context
- Stock-based compensation amounted to 6.6% of revenue in FY2025, down 1.2 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -2.3% holds above the trailing-twelve-month pace of -24.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 2.71M USD
- Year-over-year change
- +3.4%
- 4-year CAGR
- +0.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.71M | +3.4% |
| FY2024 | 2024-12-31 | 2.62M | -5.2% |
| FY2023 | 2023-12-31 | 2.77M | -10.1% |
| FY2022 | 2022-12-31 | 3.08M | +13.7% |
| FY2021 | 2021-12-31 | 2.71M | — |
Stock-Based Compensation vs competitors
How KRMD compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -24.3% is the 7th highest of 10, against a peer median of -1.6%.
- Stock-based compensation amounts to 4.6% of revenue for KRMD, versus a peer median of 3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.45M USD | -1.6% | -90.4% | 10.1% | |
| LTM Mar 2026 | $9.98M USD | +67.1% | +191.7% | 22.2% | |
| LTM Mar 2026 | $5.55M USD | +98.0% | +9.0% | 29.4% | |
| LTM Mar 2026 | $5.4M USD | -5.3% | -7.8% | 3.6% | |
| LTM Mar 2026 | $4.49M USD | -0.5% | +4.5% | 3.2% | |
| LTM Mar 2026 | $1.98M USD | -24.3% | -4.1% | 4.6% | |
| LTM Mar 2026 | €887K EUR | -82.2% | — | 5.4% | |
| LTM Mar 2026 | $706K USD | -76.8% | — | 2.2% | |
| LTM Mar 2026 | $411K USD | +58.7% | +26.8% | 1.1% | |
| LTM Mar 2026 | $141K USD | -98.0% | — | 0.1% | |
| Peer median (excluding KRMD) | — | -1.6% | +6.7% | 3.6% | |
Competitors are the stored peer set for KRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.56M) | (8.66M) | (13.74M) | (6.07M) | (2.64M) |
| Depreciation & Amortization | 463.13K | 587.14K | 870.39K | 888.47K | 810.5K |
| Deferred Income Tax | (1.82M) | (2.03M) | 3.97M | 0 | 0 |
| Stock-Based Compensation | 2.71M | 3.08M | 2.77M | 2.62M | 2.71M |
| Change in Working Capital | (1.11M) | 1.4M | 1.2M | 1.97M | (319.17K) |
| Accounts Receivables | (1.74M) | (220.17K) | 457.18K | (1.68M) | (489.2K) |
| Inventory | 723.43K | (298.53K) | 2.92M | 677.63K | (874.46K) |
| Accounts Payables | 602.61K | 1.16M | (1.42M) | 674.78K | 617.5K |
| Other Working Capital | (698.28K) | 758.15K | (760.19K) | 2.3M | 426.99K |
| Other Non-Cash Items | (1.01K) | 212.55K | 37.82K | 259.55K | (104.54K) |
| Operating Cash Flow | (4.32M) | (5.4M) | (4.89M) | (319.72K) | 462.41K |
| Capital Expenditures | (375.23K) | (2.8M) | (814.6K) | (1.3M) | (932.52K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (19.99K) | (40.51K) | (31.65K) | (35.62K) | (17.27K) |
| Investing Cash Flow | (366.17K) | (2.8M) | (814.6K) | (1.33M) | (949.79K) |
| Debt Repayment | 505.94K | (127.14K) | (218.87K) | (107.96K) | (379.98K) |
| Common Stock Issued | 2.2M | 406.62K | 0 | 0 | 186.17K |
| Common Stock Repurchased | 0 | 0 | 0 | (97.38K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | (43.19K) | (27.54K) |
| Financing Cash Flow | 2.71M | 279.49K | (218.87K) | (248.53K) | (221.35K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.98M) | (7.93M) | (5.93M) | (1.9M) | (708.74K) |
| Free Cash Flow | (4.69M) | (8.21M) | (5.71M) | (1.62M) | (470.11K) |
KORU Medical Systems, Inc.
NASDAQ:KRMD
Intrinsic Alpha fair value
Locked
Current Price
$3.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.